PExA’s Research Instrument for Lung Cancer Detection Highlighted by Sweden’s Largest Radio News Programme
The research conducted by Professor Sandra Lindstedt and her team at Lund University, using PExA’s patented research instrument, received significant attention on Sunday in Sveriges Radio’s “Kvart i fem–Ekot” (the Quarter-to-Five News). The programme reported that the Lund researchers have identified a new and simple way to detect lung cancer, which could improve opportunities for earlier detection and thereby survival.
Kvart i fem–Ekot is Sweden’s largest daily radio news broadcast, reaching approximately two million listeners. In Sunday’s edition, Professor Lindstedt was interviewed about the research conducted by her and her team at Lund University. The group uses PExA’s research instrument to collect biological samples from the lower airways through ordinary exhaled breath.
Traditional methods for detecting lung cancer require extensive procedures, and tumours must have grown to a certain size before they can be identified using standard CT scans. According to Professor Lindstedt, early detection significantly improves the chances of surviving lung cancer. By instead analysing exhaled air, cancer may be detected before it begins to grow.
- What we have seen is that when cancer is beginning to form—even before it becomes an actual tumour—the environment already shows signs that something is wrong, Professor Lindstedt says in the Ekot interview.
Professor Lindstedt and her team were recently awarded a total of SEK 27 million in research funding from the Swedish Cancer Society (Cancerfonden), something PExA previously communicated in a press release on 14 November.
- It is extremely important that this research and our technology receive attention, as it represents an important step towards the future of diagnostics, where early and non-invasive sampling can help save lives, says Tomas Gustafsson, CEO of PExA.
Link to Sveriges Radio’s Kvart i fem–Ekot on 16 November (Swedish):
https://www.sverigesradio.se/avsnitt/ekot-1645-kds-riksting-och-cs-stamma-avslutades-under-eftermiddagen
(Listen at the beginning of the programme and at 10:40.)
Link to the P4 Malmöhus report (Swedish):
https://www.sverigesradio.se/artikel/upptackt-lundaforskare-fann-tidig-lungcancer-i-andedrakt
Earlier press release about the Swedish Cancer Society’s grant to Professor Lindstedt’s group:
https://pexa.se/en/sek-27-million-from-the-swedish-cancer-society-awarded-to-sandra-lindstedts-team-in-lund-for-early-detection-of-lung-cancer/
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.